Welcome to our dedicated page for Applied Dna Scie SEC filings (Ticker: APDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a company that turns PCR enzymes into industrial-scale synthetic DNA, operates a CLIA-certified molecular diagnostics lab, and tags global cotton with forensic codes is no small task. Applied DNA Sciences weaves biotechnology with supply-chain security, so its SEC filings often span advanced R&D, regulatory lab operations, and licensing for its CertainT platform. Sifting through these multilayered disclosures can feel like decoding a genome.
Whether you need the Applied DNA Sciences annual report 10-K simplified, to dissect an Applied DNA Sciences quarterly earnings report 10-Q filing, or to see how recent Applied DNA Sciences 8-K material events explained future cash needs, our page brings every document into focus. Curious about executive pay? The Applied DNA Sciences proxy statement executive compensation section is one click away. Monitoring insider activity? Get Applied DNA Sciences insider trading Form 4 transactions and Applied DNA Sciences Form 4 insider transactions real-time. Investors regularly search 鈥淎pplied DNA Sciences SEC filings explained simply鈥� or 鈥渦nderstanding Applied DNA Sciences SEC documents with AI鈥�; this hub answers those questions while delivering Applied DNA Sciences earnings report filing analysis you can trust.
How Stock Titan鈥檚 AI helps you act faster:
- AI-powered summaries translate biotech jargon into plain English, highlighting revenue drivers like Linea DNA and mRNA production.
- AG真人官方-time alerts the moment a Form 4 or 8-K is posted, so you can track Applied DNA Sciences executive stock transactions Form 4 without delay.
- Side-by-side comparisons reveal quarter-over-quarter trends across therapeutic DNA, MDx testing, and CertainT tagging segments.
- Search inside any filing to pinpoint R&D spending, clinical milestones, or supply-chain agreements in seconds.
Save hours parsing PDFs and focus on what matters: clear, timely insight into a biotech innovator鈥檚 next move.
Applied DNA Sciences (APDN) discloses that a group of affiliated investment entities and individuals led by Anson controls 573,538 shares, representing 8.2% of the outstanding common stock on a diluted basis including warrants. The filing states the position is held in the ordinary course of business and not for the purpose of changing control. Shared voting and dispositive power over the 573,538 shares is reported, with no sole voting or dispositive power claimed. The filing identifies the reporting persons and their organizational domiciles and clarifies warrant exercise limitations considered in the ownership percentage.
Applied DNA Sciences, Inc. implemented significant corporate and capital-structure actions in fiscal 2025 while restructuring operations to focus on Therapeutic DNA Production Services. The company completed two reverse stock splits (board-authorized 1-for-50 then 1-for-15, effective June 2, 2025) that adjusted warrant exercise prices and share counts. Since January 2025 the company has reduced headcount by 39%, expects a projected 31% reduction in payroll expenses versus fiscal 2024, and recorded approximately $305,000 and an additional $300,000 in one-time charges related to workforce reductions and ceasing ADCL operations; ADCL is accounted for as discontinued operations.
Revenue and receivables show high customer concentration (e.g., 26%, 23%, 12% in key segments; three customers represented 82% of accounts receivable at June 30, 2025). The company completed an October registered/direct offering with instruments priced at $240.00 (pre-funded warrants exercised during the period) and agreed to placement agent fees of 6% plus warrants. Lease and cash commitments include a $750,000 standby letter of credit and rent expense of $157,320 and $498,416 for the three- and nine-month periods ended June 30, 2025.
FAQ
What is the current stock price of Applied Dna Scie (APDN)?
What is the market cap of Applied Dna Scie (APDN)?
